173 related articles for article (PubMed ID: 36281741)
1. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Hillion S; Konig MF; Moura MC; Hummel AM; Carmona E; Peikert T; Fervenza FC; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; Brunetta P; St Clair EW; Harris KM; Stone JH; Grandi G; Pers JO; Specks U; Cornec D
Arthritis Rheumatol; 2023 May; 75(5):736-747. PubMed ID: 36281741
[TBL] [Abstract][Full Text] [Related]
2. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
4. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
5. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
6. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
Front Immunol; 2020; 11():2053. PubMed ID: 33013868
[No Abstract] [Full Text] [Related]
8. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
9. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Gamerith G; Mildner F; Merkel PA; Harris K; Cooney L; Lim N; Spiera R; Seo P; Langford CA; Hoffman GS; St Clair EW; Fervenza FC; Monach P; Ytterberg SR; Geetha D; Amann A; Wolf D; Specks U; Stone JH; Kronbichler A
Ann Rheum Dis; 2023 Feb; 82(2):253-261. PubMed ID: 35973802
[TBL] [Abstract][Full Text] [Related]
10. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
[TBL] [Abstract][Full Text] [Related]
12. Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis.
Berti A; Hillion S; Hummel AM; Son YM; Chriti N; Peikert T; Carmona EM; Abdulahad WH; Heeringa P; Harris KM; St Clair EW; Brunetta P; Fervenza FC; Langford CA; Kallenberg CG; Merkel PA; Monach PA; Seo P; Spiera RF; Stone JH; Grandi G; Sun J; Pers JO; Specks U; Cornec D;
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34618687
[TBL] [Abstract][Full Text] [Related]
13. A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
McClure ME; Gopaluni S; Wason J; Henderson RB; Van Maurik A; Savage CCO; Pusey CD; Salama AD; Lyons PA; Lee J; Mynard K; Jayne DR; Jones RB;
Trials; 2023 Mar; 24(1):180. PubMed ID: 36906660
[TBL] [Abstract][Full Text] [Related]
14. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
15. Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls.
Cornec D; Berti A; Hummel A; Peikert T; Pers JO; Specks U
J Autoimmun; 2017 Nov; 84():122-131. PubMed ID: 28870527
[TBL] [Abstract][Full Text] [Related]
16. Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity.
Chen DP; McInnis EA; Wu EY; Stember KG; Hogan SL; Hu Y; Henderson CD; Blazek LN; Mallal S; Karosiene E; Peters B; Sidney J; James EA; Kwok WW; Jennette JC; Ciavatta DJ; Falk RJ; Free ME
J Am Soc Nephrol; 2022 Aug; 33(8):1517-1527. PubMed ID: 35672132
[TBL] [Abstract][Full Text] [Related]
17. Identification of proteinase 3 autoreactive CD4
Sharma RK; Yoosuf N; Afonso M; Scheffschick A; Avik A; Bartoletti A; Horuluoglu B; Diaz Boada JS; Boddul SK; Jonasdottir AD; Lövström B; Brauner H; Raposo B; Chemin K; Bruchfeld A; Gunnarsson I; Malmström V
Kidney Int; 2023 May; 103(5):973-985. PubMed ID: 36804380
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
